Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery.

AlSuleimani YM, Hiley CR.

Eur J Pharmacol. 2013 Feb 28;702(1-3):1-11. doi: 10.1016/j.ejphar.2013.01.006. Epub 2013 Jan 20.

PMID:
23340219
3.
4.

Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity.

Wheal AJ, Alexander SP, Randall MD.

Br J Pharmacol. 2010 Jun;160(3):701-11. doi: 10.1111/j.1476-5381.2010.00770.x.

5.

Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries.

Sudhahar V, Shaw S, Imig JD.

Eur J Pharmacol. 2009 Apr 1;607(1-3):143-50.

6.

Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, Baker D, Selwood DL, Hiley CR.

Br J Pharmacol. 2007 Nov;152(5):751-64. Epub 2007 Sep 24.

8.

Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery.

Al Suleimani YM, Al Mahruqi AS, Hiley CR.

Eur J Pharmacol. 2015 Oct 15;765:107-14. doi: 10.1016/j.ejphar.2015.08.021. Epub 2015 Aug 18.

PMID:
26297305
9.

The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

AlSuleimani YM, Hiley CR.

Br J Pharmacol. 2015 Jun;172(12):3043-57. doi: 10.1111/bph.13107. Epub 2015 Apr 24.

10.

Role of Ca2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis.

Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, Lee FY, Lee SD.

Liver Int. 2007 Oct;27(8):1045-55.

PMID:
17845532
11.

Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries.

O'Sullivan SE, Kendall DA, Randall MD.

Br J Pharmacol. 2004 Jun;142(3):435-42. Epub 2004 May 17.

12.

Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries.

Wheal AJ, Alexander SP, Randall MD.

Eur J Pharmacol. 2012 Jan 15;674(2-3):384-90. doi: 10.1016/j.ejphar.2011.11.033. Epub 2011 Nov 29.

PMID:
22154756
13.

Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Herradón E, Martín MI, López-Miranda V.

Br J Pharmacol. 2007 Nov;152(5):699-708. Epub 2007 Aug 20.

14.

'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors.

Ho WS, Barrett DA, Randall MD.

Br J Pharmacol. 2008 Nov;155(6):837-46. doi: 10.1038/bjp.2008.324. Epub 2008 Aug 11.

15.
16.

Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.

Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V.

Br J Pharmacol. 2004 Jun;142(3):509-18. Epub 2004 May 17.

17.

N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels.

Parmar N, Ho WS.

Br J Pharmacol. 2010 Jun;160(3):594-603. doi: 10.1111/j.1476-5381.2009.00622.x. Epub 2010 Feb 5.

18.

Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries.

Chataigneau T, Félétou M, Thollon C, Villeneuve N, Vilaine JP, Duhault J, Vanhoutte PM.

Br J Pharmacol. 1998 Mar;123(5):968-74.

19.

Cytochrome P450 pathway contributes to methanandamide-induced vasorelaxation in rat aorta.

López-Miranda V, Dannert MT, Herradón E, Alsasua A, Martín MI.

Cardiovasc Drugs Ther. 2010 Dec;24(5-6):379-89. doi: 10.1007/s10557-010-6261-9.

PMID:
20814734
20.

The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant.

Al Suleimani YM, Al Mahruqi AS.

Eur J Pharmacol. 2017 Jan 5;794:209-215. doi: 10.1016/j.ejphar.2016.11.040. Epub 2016 Nov 24.

PMID:
27890711

Supplemental Content

Support Center